Advocacy intelligence hub — real-time data for patient organizations
Michał Jaśkiewicz
Seoul National University Hospital — NA
Normocarb HF: FDA approved
Use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace water and to correct electrolytes and acid-base imbalances in adults and children
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Normocarb HF
Dialysis Solutions, Inc.
Normocarb HF
(bicarbonate infusate)Orphan drugDialysis Solutions, Inc.
Flavio Mantelli, MD, PhD
Dompé farmaceutici S.p.A., Milan
David Liao, MD, PhD
Retina-Vitreous Associates Medical Group
Daniel X Hammer, Ph.D.
Food and Drug Administration (FDA)
Fnu Ruchi, Ph.D.
National Eye Institute (NEI)
Laura Andres-Martin, PhD
New York Stem Cell Foundation Research Institute
Shyamanga Borooah, MD
Shiley Eye Institute
📍 SAN DIEGO, CA